The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 140.00
Ask: 160.00
Change: 5.00 (3.45%)
Spread: 20.00 (14.286%)
Open: 150.00
High: 150.00
Low: 150.00
Prev. Close: 145.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

14 May 2019 07:01

RNS Number : 8798Y
Faron Pharmaceuticals Oy
14 May 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Faron Pharmaceuticals Ltd

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Timo Syrjälä

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

13.05.2019

6. Date on which issuer notified (DD/MM/YYYY):

13.05.2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

12.14%

12.14%

37.233.894

Position of previous notification (if

applicable)

7.05%

7.05%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

FI4000153309

1.789.025

2.730.350

4.80%

7.33%

SUBTOTAL 8. A

4.519.375

12.14%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Timo Syrjälä (Direct)

4.80%

4.80%

Acme Investments SPF Sarl (Indirect)

7.33%

7.33%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Share subscription 1.757.375 shares on 13.5.2019

 

Place of completion

Lausanne

Date of completion

13/05/2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLQXLFFKEFFBBD
Date   Source Headline
28th Jun 20227:00 amRNSAnnouncement of Placing
16th Jun 202212:00 pmRNSFaron notice of EGM
15th Jun 20227:00 amRNSFaron Announces Top-Line 12-Month Survival Results
8th Jun 20227:00 amRNSFirst Patient Dosed in Ph I/II BEXMAB Combo Study
1st Jun 20227:00 amRNSExercise of options
30th May 20227:00 amRNSPresentation of Biomarker Analysis at ASCO
16th May 20227:00 amRNSFDA and FIMEA approve BEXMAB study to begin
12th May 20223:50 pmRNSEx Vivo Data Presented at EHA2022 Congress
9th May 20227:00 amRNSMol Cancer Ther Publishes Bexmarilimab Research
4th May 202211:15 amRNSGrant of options
22nd Apr 20221:01 pmRNSBoard Changes
22nd Apr 20221:00 pmRNSResults of AGM
21st Apr 20224:30 pmRNSFaron Presents Melanoma Data at EADO
8th Apr 20223:45 pmRNSManagers’ Transactions
5th Apr 20227:00 amRNSFaron Closes HIBISCUS Trial
25th Mar 20229:00 amRNSNotice of Faron Pharmaceuticals Ltd’s AGM
25th Mar 20227:15 amRNSFaron´s Annual Report 2021 Published
25th Mar 20227:00 amRNSFinancial Statement January 1 to December 31 2021
14th Mar 20227:00 amRNSFaron Publishes Research From INTEREST Trial
9th Mar 20227:00 amRNSPresentation of Biomarker Data at AACR 2022
7th Mar 20227:00 amRNSNotice of 2021 Full-Year Results and Annual Report
4th Mar 20227:00 amRNSFaron presents at upcoming conferences
28th Feb 20225:45 pmRNSFaron Board Issues Warrants to IPF Partners
28th Feb 20227:00 amRNSFaron Obtains Debt Funding from IPF Partners
23rd Feb 20227:00 amRNSFaron Updates on Bexmarilimab Development Program
14th Feb 20227:00 amRNSFaron Announces R&D Day
3rd Feb 202210:40 amRNSScientific Reports Publishes INFORAAA Results
31st Jan 20221:30 pmRNSHoldings in Company
31st Jan 20227:00 amRNSJuho Jalkanen Appointed Chief Operating Officer
28th Jan 20227:00 amRNSGrant of options
24th Jan 20227:00 amRNSFaron at Proactive One2One Investor Forum
17th Jan 20227:00 amRNSFaron to Present at Redeye Fight Cancer Seminar
5th Jan 20227:00 amRNSFaron to Present at H.C. Wainwright BioConnect
4th Jan 20227:00 amRNSFaron Appoints Marie-Louise Fjällskog as CMO
21st Dec 20217:00 amRNSFaron’s financial calendar for 2022
9th Dec 20217:00 amRNSFaron Announces Topline MATINS Biomarker Analysis
1st Dec 20217:00 amRNSChange in Faron’s Management Team
16th Nov 20217:00 amRNSFaron to Present at Jefferies Conference 2021
9th Nov 20217:00 amRNSFaron awarded EUR 3.8 Million in Arbitration Case
3rd Nov 20213:55 pmRNSCellular and Molecular Life Sciences Publication
7th Oct 20217:00 amRNSExercise of options
5th Oct 202111:30 amRNSHolding(s) in Company
1st Oct 20212:00 pmRNSRegistration of Placing Shares with Trade Register
1st Oct 20217:00 amRNSResults of Placing and Issue Price
30th Sep 20214:31 pmRNSProposed Issue and Placing of Shares
17th Sep 20217:00 amRNSPresentation of Updated MATINS Data at ESMO
9th Sep 20217:00 amRNSFaron Announces Presentation at ESMO Congress
7th Sep 20217:00 amRNSFaron to Present at H.C. Wainwright Conference
26th Aug 20217:00 amRNSHalf-Year Financials, January 1 – June 30 2021
25th Aug 20217:00 amRNSFirst Patient Dosed in Phase II/III COVID-19 Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.